|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues surrounding Pro566 of human Axin2|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/ml BSA, 50% glycerol|
|Contains||<0.02% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
It is not recommended to aliquot this antibody.
This antibody is not cross-reactive with Axin1.
The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.
MA5-15015 was used in western blot to determine the prognostic role of the Wnt-signaling antagonist SFRP1 in bladder cancer
|Rogler A,Kendziorra E,Giedl J,Stoehr C,Taubert H,Goebell PJ,Wullich B,Stöckle M,Lehmann J,Petsch S,Hartmann A,Stoehr R||Journal of cancer research and clinical oncology (141:1779)||2015|